Background {#Sec1}
==========

Intra-abdominal desmoid tumor develops in some patients with familial adenomatous polyposis or occurs secondary to an external stimulus such as surgical trauma \[[@CR1], [@CR2]\]. Intra-abdominal desmoid tumor has been reported after conventional laparotomy \[[@CR3]\], but few cases of intra-abdominal desmoid tumor after laparoscopic surgery have been reported \[[@CR4]--[@CR6]\]. We report herein a case of intra-abdominal desmoid tumor in the mesentery of the small intestine after laparoscopic sigmoid colectomy for sigmoid colon cancer.

Case presentation {#Sec2}
=================

A 74-year-old woman underwent laparoscopic sigmoid colectomy with D3 lymph node dissection for sigmoid cancer at our institution. She had no clinical and familial history of familial adenomatous polyposis. Sigmoid colon cancer (S, type 1, 40 × 38 mm, tub1, pT2, med, INFβ, ly1, v0, pN0 (0/11), pathological stage I) was pathologically diagnosed from the resected specimen, and the resection was curative. The patient was regularly followed up without adjuvant chemotherapy.

Eighteen months after sigmoid colectomy, a solitary abdominal tumor in the mesentery of the small intestine was detected by contrast-enhanced computed tomography (CT). The tumor was 20 mm in size, enhanced by contrast medium, and showed partly unclear boundary to adjacent tissue (Fig. [1](#Fig1){ref-type="fig"}a--c). Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19-9) levels were within the normal range. Although we suspected this tumor represented peritoneal recurrence, fluorodeoxyglucose positron emission tomography (FDG-PET) did not show abnormal uptake. Follow-up CT after 1 month showed that the tumor had enlarged to 25 mm in size (Fig. [1](#Fig1){ref-type="fig"}c). Although no pathological diagnosis was obtained, the radiologist of our hospital and the colorectal group conference of our department evaluated the tumor as a recurrent tumor, potentially peritoneal metastasis from the sigmoid colon cancer. We discussed about the treatment strategy for the patient in a conference and applied chemotherapy using capecitabine, oxaliplatin, and bevacizumab (CAPOX + bevacizumab (Bmab)) to observe the response of the tumor to chemotherapy and to examine whether other lesions suggestive of recurrence developed. Then, we fully explained the situation to the patient and her family. They accepted the treatment strategy we suggested.Fig. 1Changes in the CT findings. **a** No tumor is detected in the mesentery at 6 months after colectomy. **b** A tumor 20 mm in size was detected in the mesentery at 18 months after colectomy. CT scan showed partly unclear boundary to the surrounding tissue. **c** The tumor was enlarged up to the size of 33 mm with irregular margin after three courses of CAPOX + Bmab treatment

After administration of 3 cycles of CAPOX + Bmab, the tumor showed further enlargement. At that time, we thought that histological diagnosis of the tumor was necessary before applying second-line chemotherapy. Surgical resection of the tumor was therefore performed.

The tumor existed in the jejunal mesentery, 100 cm from the ligament of Treitz. Although invasive growth was apparent, no evidence suggested invasion to the adjacent organs. We therefore resected 40 cm of the jejunal segment together with the tumor (Fig. [2](#Fig2){ref-type="fig"}). Microscopically, the tumor comprised fibroblasts, myofibroblasts, and infiltrating inflammatory cells. Immunohistochemical staining showed positive results for β-catenin and vimentin, focally positive results for desmin and α-smooth muscle actin (α-SMA) and S-100, and negative results for CD34 and CD117 (c-kit) (Fig. [3](#Fig3){ref-type="fig"}a--d). Based on these findings, the tumor was histologically diagnosed as a desmoid tumor. As of 36 months after resection of the desmoid tumor, neither the sigmoid colon cancer nor desmoid tumor has recurred.Fig. 2Microscopic view of the resected specimen. A tumor 31 × 21 mm in size with whitish and smooth cut surface. The margin was irregularFig. 3Pathological findings of the resected specimen. **a** In hematoxylin-eosin staining, the tumor consisted of relatively homogenous spindle cells with few mitoses (\< 1%). **b** Both the cytoplasm and nucleus were positive in β-catenin staining. **c** In desmin staining, vascular smooth muscles were positive whereas tumor cells were marginally positive. **d** In c-kit staining, only mast cells were positive

Conclusions {#Sec3}
===========

Desmoid tumor is a benign condition resulting from an abdominal proliferation of myofibroblasts \[[@CR7]\]. Although well recognized as a significant complication of familial adenomatous polyposis, particularly after colectomy, desmoid tumor after colectomy for sporadic colorectal cancer is rare \[[@CR8]\]. Since surgical trauma is thought to represent an important trigger for desmoid tumor \[[@CR2]\], desmoid tumor after laparoscopic surgery may be even rarer than that after conventional laparotomy.

To the best of our knowledge, only nine cases have been reported previously in the literature, including case reports in Japanese (Table [1](#Tab1){ref-type="table"}) \[[@CR3], [@CR6], [@CR9]--[@CR15]\]. The age and gender of patients were compatible with those of patients with colorectal cancer. These cases did not necessarily occur at sites of surgical trauma. In six of nine patients, pathological stages were stage I or II, suggesting that desmoid tumor often occurs in patients with a low risk of recurrence.Table 1Reference No.AuthorYearAgeGenderSiteSize (mm)TreatmentPreoperative diagnosisCancer site^b^StageInterval (months)PrognosisRecurrence/cause of death\[7\]Kawano201070Mpre-duodenal region30resectionboth^a^AII186 m alivedisease free\[8\]Matagi201171Mpresacral region50resectionrecurrenceRI1241 m deadsepsis\[9\]Mizuno201161Manastomotic site27resectionrecurrenceAIIIb1224 m alivedisease free\[10\]Gabata201356Fabdominal cavity40resectionnon-recurrenceDIIIa1211 m alivedisease free\[11\]Hamada201470Msurface of the liver20resectionunknownA02412 m alivedisease free\[12\]Otani201565Fanastomotic site40resectionbothTII1212 m alivedisease free\[13\]Saji201566Mjejunal mesenterium24resectionbothDI2014 m alivedisease free\[14\]Kondo201566Fparaaortic region, ileocecal mesenterium150 + 90/ 60 (two lesions) ^c^resectionbothRaIIIa1212 m alivedisease free\[15\]Shimonozono201881Mgastrosplenic ligament18resectionnon-recurrenceTI1224 m alivedisease freeOur case201874Fjejunal mesenterium20resectionrecurrenceSI1830 m alivedisease free^a^both recurrence and non-recurrence were suspected^b^A: ascending colon, R: rectum, D: descending colon, T: transverse colon, Ra: upper rectum^c^a snowman-shape lesion 150 mm + 90 mm in size and a lesion 60 mm in size

In all patients, desmoid tumor developed within 2 years after the resection of colorectal cancer. Since patients after resection of colorectal cancer usually undergo regular follow-up, desmoid tumors were less than 50 mm in diameter in all except for one patient. All patients underwent surgical resection of the desmoid tumor, with exception of one patient who died of sepsis.

Mesenteric desmoid developing 18 months after laparoscopic surgery for a sporadic, stage I, sigmoid colon cancer, as in our patients, is rare \[[@CR16]--[@CR18]\], and we did not consider the possibility of desmoid tumor until surgical resection. Under the suspicion of peritoneal dissemination, we performed systemic chemotherapy using CAPOX + Bmab to both treat the tumor and observe the response of the tumor. During the 3 cycles of CAPOX + Bmab treatment, no recurrence tumors were identified. Moreover, tumor size was increased, suggesting a necessity for changing the chemotherapeutic regimen. Because the tumor was still resectable at that time, we determined to perform tumor resection before proceeding to chemotherapy using a second-line regimen.

Even during the resection, we did not consider the possibility of a desmoid tumor. We initially tried to perform enucleation of the tumor 50 mm in diameter and had to resect a 44-cm segment of the jejunum due to the impaired blood supply to that jejunal segment. Actually, the diagnosis of desmoid tumor was obtained by rapid pathological diagnosis during surgery. Since radical resection is the gold standard for the treatment of desmoid tumor \[[@CR19]\], the inclusion of the jejunal segment in the resection was considered to be beneficial in terms of local recurrence.

The patient has experienced no recurrence of either colon cancer or desmoid tumor as of 36 months after resection of the desmoid tumor. Because the local recurrence rate of desmoid tumor is reportedly high \[[@CR2], [@CR19], [@CR20]\], we are still conducting careful follow-up using CT at an interval of at least 6 months, particularly for detecting local recurrence of desmoid tumor.

In summary, we have reported herein a case with mesenteric desmoid tumor after laparoscopic resection of stage I sigmoid colon cancer. In case a recurrence is suspected, even if curative resection may be possible, chemotherapy can be the treatment of choice because the risk of development of subsequent further metastatic lesions is high. Although we performed systemic chemotherapy under a diagnosis of recurrence, short-term neoadjuvant chemotherapy might have limited adverse events. We concluded that the possibility of desmoid should be included among the differential diagnoses of the tumor, in particular, if an intra-abdominal mass is found during the follow-up for resection of colorectal cancer with a low risk of recurrence.
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